22 August 2026 in Veterinary and Comparative Oncology
Although osteosarcoma is the most common primary bone tumour in dogs, involvement of the pelvic bones is rare. The aim of the present study was to describe clinical presentation, identify possible prognostic factors, and evaluate outcomes in dogs diagnosed with pelvic osteosarcoma. Seventy‐four dogs with cytologically or histologically diagnosed pelvic osteosarcoma were included in this multicentre retrospective study (2007–2025). The median progression‐free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method, with comparisons performed using log‐rank tests. Prognostic factors for PFS and OS were assessed using multivariable Cox proportional hazards regression analysis. Lameness (84%) was the most common presenting clinical sign, and the ilium (57%) was the most frequent intrapelvic tumour location. Thirty‐one percent of dogs had metastases at diagnosis, primarily affecting the lungs. The median PFS was 75 days, and the median OS was 79 days. Dogs receiving any treatment had significantly longer PFS (116 vs. 7 days, p < 0.001) and OS (145 vs. 8 days, p < 0.001) than untreated dogs. No factors were significantly associated with PFS. In contrast, dogs with higher body weight and shorter time to diagnosis tended to have more favourable survival, whereas chemotherapy and local progression were associated with poorer outcomes. Despite the overall poor prognosis associated with pelvic osteosarcoma, treatment may extend survival. An individualized, often multimodal approach may provide clinical benefit in selected dogs.
2 March 2026 in Journal of Veterinary Internal Medicine
Background: Traditional measures of treatment success for radiotherapy in dogs with intracranial neoplasia include progression-free and overall survival time. Although important, these measures do not reflect neurologic function. Hypothesis/Objectives: Assess tumor shrinkage by follow-up imaging and outcome using 2 neurodisability scoring systems—1 validated and 1 simplified. Animals: One hundred six dogs with imaging-diagnosed intracranial tumors treated with 10-fraction definitive-intent radiotherapy. Methods: Data were collected from 2 randomized trials. Neurologic function was prospectively assessed using a validated score, and a retrospective simplified score was added. Imaging was recommended every 6 months or upon clinical decline. Results: Diagnoses included extraparenchymal tumors (45.3%), intraparenchymal tumors (35.8%), and pituitary tumors (18.9%). Median follow-up was 581 days. The neurodisability score improved significantly before radiotherapy (median 1.0, P = .04) because of medical management, and again during treatment (median 0.0, P < .01). At peak response, 76% of dogs had no or only mild neurologic deficits. Tumor volume significantly decreased at 6 and 12 months (P < .01): median shrinkage at 6 months was −39% (extraparenchymal tumors), −83% (intraparenchymal tumors), and −47% (pituitary tumors). A moderate correlation between tumor reduction and neurodisability score was seen only at 6 months (r = 0.395, P = .002). Results were consistent across protocols. Conclusions and clinical importance: Radiotherapy led to lasting neurologic improvement and substantial tumor reduction. Neurologic function did not always correlate with tumor volume shrinkage, emphasizing the importance of incorporating and prioritizing neurologists’ functional assessments in posttreatment evaluation.